Your browser doesn't support javascript.
loading
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients / Tolerabilidade e eficácia da fluoxetina, metformina e sibutramina na redução de parâmetros antropométricos e metabólicos em pacientes obesos
Guimarães, Camila; Pereira, Leonardo R. L; Iucif Júnior, Nélson; Cesarino, Evandro José; Almeida, Carlos A. N. de; Carvalho, Dermeval de; Queiroz, Regina H. C.
  • Guimarães, Camila; Faculty of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical, Toxicological and Bromatological Analysis. Ribeirão Preto. BR
  • Pereira, Leonardo R. L; Faculty of Pharmaceutical Sciences of Ribeirão Preto. Department of Pharmaceutical Sciences. Ribeirão Preto. BR
  • Iucif Júnior, Nélson; University of Ribeirão Preto. Faculty of Medicine. Ribeirão Preto. BR
  • Cesarino, Evandro José; Faculty of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical, Toxicological and Bromatological Analysis. Ribeirão Preto. BR
  • Almeida, Carlos A. N. de; University of Ribeirão Preto. Faculty of Medicine. Ribeirão Preto. BR
  • Carvalho, Dermeval de; Faculty of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical, Toxicological and Bromatological Analysis. Ribeirão Preto. BR
  • Queiroz, Regina H. C; Faculty of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical, Toxicological and Bromatological Analysis. Ribeirão Preto. BR
Arq. bras. endocrinol. metab ; 50(6): 1020-1025, dez. 2006. tab
Article in English, Portuguese | LILACS | ID: lil-439720
ABSTRACT
The aim of this study is to assess the effects of sibutramine (S) 15 mg/day, fluoxetine (F) 60 mg/day, and metformin (M) 1,700 mg/day, as an adjunct therapy to a 1,500 kcal/day diet, in reducing anthropometric and metabolic parameters. S (n= 8), F (n= 9), and M (n= 8) were compared to placebo (n= 10) in 35 obese patients in a 90-day trial. Side effects were also studied during the treatment. The data demonstrated that F therapy resulted in a greater average reduction in BMI (11.0 percent), weight (10.0 percent), abdominal circumference (11.0 percent) and percentfatty-tissue (12.8). An elevation in HDL-cholesterol (25.8 percent) and a reduction in average triglyceride levels (28.3 percent) were also shown. S presented a 7.91 percent reduction in the abdominal circumference and a 9.65 reduction in percentfatty-tissue was also found. M group presented reductions in BMI (4.03 percent), waist circumference (6.92 percent), HOMA (23.5 percent) and blood pressure (6.08 percent in systolic and 2.08 percent in diastolic). In general, the three drugs can be considered well tolerated. We concluded that F and S demonstrated a greater mean reduction in anthropometric and metabolic parameters when compared to M, however all of them are useful for that purpose, when the subjectsÆ characteristics are considered.
RESUMO
O objetivo deste estudo foi avaliar o efeito da sibutramina (S) 15 mg/dia, fluoxetina (F) 60 mg/dia, e metformina (M) 1.700 mg/dia, associadas a uma dieta de 1.500 kcal/dia, na redução de parâmetros antropométricos e metabólicos. S (n= 8), F (n= 9) e M (n= 8) foram comparadas ao placebo (n= 10) em 35 pacientes obesos durante 90 dias de tratamento. As reações adversas também foram avaliadas durante o tratamento. O grupo F demonstrou uma redução no IMC (11,0 por cento), peso (10,0 por cento), circunferência abdominal (11,0 por cento) e por cento de tecido adiposo (12,8). Também foram observados um aumento nos níveis de HDL-colesterol (25,8 por cento) e uma redução nos níveis de triglicérides (28,3 por cento), no grupo F. O grupo S apresentou uma redução de 7,91 por cento na circunferência abdominal e de 9,65 na por cento de tecido adiposo. Já o grupo M apresentou reduções no IMC (4,03 por cento), circunferência abdominal (6,92 por cento), HOMA (23,5 por cento) e pressão arterial (6,08 por cento na sistólica, 2,08 por cento na diastólica). Os três fármacos analisados foram bem tolerados durante o tratamento. Concluímos que a F e a S demonstraram maior eficácia na redução dos parâmetros antropométricos e metabólicos dos pacientes obesos quando comparadas à M, entretanto todas podem ser prescritas para essa finalidade, desde que sejam consideradas as características individuais dos pacientes.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Appetite Depressants / Cholesterol / Antidepressive Agents, Second-Generation / Hypoglycemic Agents / Obesity Type of study: Controlled clinical trial Limits: Adolescent / Adult / Humans / Male Language: English / Portuguese Journal: Arq. bras. endocrinol. metab Journal subject: Endocrinology / Metabolism Year: 2006 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculty of Pharmaceutical Sciences of Ribeirão Preto/BR / University of Ribeirão Preto/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Appetite Depressants / Cholesterol / Antidepressive Agents, Second-Generation / Hypoglycemic Agents / Obesity Type of study: Controlled clinical trial Limits: Adolescent / Adult / Humans / Male Language: English / Portuguese Journal: Arq. bras. endocrinol. metab Journal subject: Endocrinology / Metabolism Year: 2006 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculty of Pharmaceutical Sciences of Ribeirão Preto/BR / University of Ribeirão Preto/BR